Cardiff Oncology Inc expected to post a loss of 28 cents a share - Earnings Preview

Cardiff Oncology

01/11/2023 02:41

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The San Diego California-based  company is expected to
report  a
46.2% decrease in revenue to $50 thousand from $93 thousand a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Cardiff Oncology
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $8.5​, above​ its last closing price of $1.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.28       -0.26      -0.25     Beat    3.5
 Mar. 31 2023  -0.22       -0.23      -0.25     Missed  -10.6
 Dec. 31 2022  -0.22       -0.23      -0.20     Beat    14.9​
 Sep. 30 2022  -0.27       -0.26      -0.20     Beat    24.2
 ​​Jun.        -0.26       -0.25      -0.24     Beat    4.8
 30 2022                                                
 Mar. 31 2022  -0.25       -0.23      -0.25     Missed  -8.2​
 Dec. 31 2021  -0.17       -0.17      -0.23     Missed  -34
 Sep. 30 2021  -0.17       -0.17      -0.17     Met     0
 This summary was machine generated November 1 at 02:41 GMT.  All
figures in US dollars  unless otherwise stated